naulicreative-shutterstock-com-brexit-

naulicreative / Shutterstock.com

3 November 2016Big Pharma

‘Hard’ Brexit could delay new drugs for UK, says report

Stephen Dorrell, the former UK health minister, has warned in a report for Public Policy Projects that a “hard Brexit” deal could affect Britain’s access to new drugs.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts